Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

NCT06617897

Status	RECRUITING
Phase	Phase 3
Sponsor	CSL Behring
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (3)

- • Aged \>= 18 years at the time of providing written informed consent.
- • Diagnosis of PMP requiring CRS with HIPEC.
- • Bleeding risk: Predicted intraoperative blood loss of \>=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)

Exclusion (9)

- • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
- • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery.
- • Known history of chronic hepatitis.
- • Clopidogrel or ticagrelor administration within 5 days before study surgery.
- • Prasugrel administration within 7 days before study surgery.

... and 4 more (see full listing online)

Locations (1 total)

Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom